STOCK TITAN

NeuroSense Therapeutics Ltd. - $NRSN STOCK NEWS

Welcome to our dedicated page for NeuroSense Therapeutics Ltd. news (Ticker: $NRSN), a resource for investors and traders seeking the latest updates and insights on NeuroSense Therapeutics Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroSense Therapeutics Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroSense Therapeutics Ltd.'s position in the market.

Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announces scientific presentations at three upcoming conferences, including the Society of Neuroscience's annual conference and the 34th International Symposium on ALS/MND. The last patient has completed the double-blind segment of PARADIGM, with clinical efficacy results expected in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
-
Rhea-AI Summary
NeuroSense Therapeutics has completed dosing of the last patient in the double-blind segment of its Phase 2b ALS trial of PrimeC. The company expects to release clinical efficacy results and safety results in December 2023. They also plan to report on the assessment of ALS-biomarkers in H1 2024 and collaborate with Biogen for biomarker analysis. PrimeC has shown promising results in previous trials and has been granted Orphan Drug Designation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.93%
Tags
-
Rhea-AI Summary
NeuroSense Therapeutics Ltd. announced that its Chief Medical Officer, Dr. Ferenc Tracik, will participate in the 29th annual BIO-Europe Fall partnering conference in Munich, Germany. The company's lead drug, PrimeC, is in a global Phase 2b study for ALS, with other programs targeting Alzheimer's and Parkinson's diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
Rhea-AI Summary
NeuroSense Therapeutics' lead drug candidate, PrimeC, has been confirmed to be effective in treating ALS by a renowned ALS researcher.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
News
Rhea-AI Summary
NeuroSense Therapeutics provides an update on clinical and operational developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
-
Rhea-AI Summary
NeuroSense's PrimeC shows significant increase in survival rate of induced motor neurons in ALS study, reinforcing previous findings. PrimeC performed among the best in improving motor neuron survival compared to other ALS drugs. Clinical topline results from Phase 2b study expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
none
Rhea-AI Summary
NeuroSense terminates equity offering program, fully funded into Q2 2024; ALS Phase 2b trial data expected Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary
NeuroSense opens EU office and receives SME status from EMA, offering regulatory guidance and engagement. Plans to enroll patients in Phase 3 ALS study. Clinical results from Phase 2b study expected end of 2023. Commences global Phase 3 study in 2024 with numerous European sites. Financial benefits include fee reductions and exemptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
Rhea-AI Summary
NeuroSense receives key patent for ALS treatment drug combination
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
Rhea-AI Summary
NeuroSense to present PARADIGM Phase 2b ALS study at conferences, expects to report topline results in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences
NeuroSense Therapeutics Ltd.

Nasdaq:NRSN

NRSN Rankings

NRSN Stock Data

19.48M
10.65M
28.05%
0.91%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Herzliya

About NRSN

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa